MASTL
Basic information
Region (hg38): 10:27154824-27187953
Links
Phenotypes
GenCC
Source:
- autosomal thrombocytopenia with normal platelets (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Thrombocytopenia 2 | AD | Hematologic | Individuals may have bleeding tendency, and precautions (eg, in surgical situations) may be beneficial | Hematologic | 10891439; 12890928; 22102272 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MASTL gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 20 | |||||
missense | 49 | 13 | 71 | |||
nonsense | 2 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 1 | 2 | 3 | |||
non coding | 13 | 29 | 49 | |||
Total | 0 | 0 | 71 | 28 | 44 |
Variants in MASTL
This is a list of pathogenic ClinVar variants found in the MASTL region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
10-27154826-T-A | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27154859-G-A | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27154946-C-T | Thrombocytopenia | Benign/Likely benign (Jun 19, 2021) | ||
10-27155080-CG-C | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155082-T-C | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155173-T-G | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155187-G-A | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155201-G-A | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155228-G-C | Thrombocytopenia | Benign/Likely benign (Jun 19, 2021) | ||
10-27155257-C-T | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155270-C-T | Thrombocytopenia | Uncertain significance (Jun 14, 2016) | ||
10-27155311-C-CG | Thrombocytopenia | Likely benign (Jun 14, 2016) | ||
10-27155321-T-C | Thrombocytopenia | Likely benign (Jun 14, 2016) | ||
10-27155374-G-A | Thrombocytopenia | Benign (Jun 19, 2021) | ||
10-27155399-C-A | not specified • Thrombocytopenia | Benign (Jun 19, 2021) | ||
10-27155400-T-C | not specified • Thrombocytopenia | Benign (Jun 19, 2021) | ||
10-27155415-T-G | not specified • Thrombocytopenia | Benign (Jun 19, 2021) | ||
10-27155458-C-T | not specified | Uncertain significance (Jul 11, 2023) | ||
10-27155460-G-C | not specified • Thrombocytopenia | Benign/Likely benign (Apr 10, 2018) | ||
10-27155535-A-C | MASTL-related disorder | Uncertain significance (Jan 08, 2023) | ||
10-27155536-T-C | Thrombocytopenia | Uncertain significance (Jan 12, 2018) | ||
10-27155649-C-T | not specified | Benign (Jun 19, 2021) | ||
10-27155777-A-T | Benign (Jun 19, 2021) | |||
10-27155834-C-A | Benign (Jun 19, 2021) | |||
10-27158276-T-C | Benign (Jun 20, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MASTL | protein_coding | protein_coding | ENST00000375940 | 12 | 32101 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
5.44e-13 | 0.798 | 125618 | 0 | 130 | 125748 | 0.000517 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.505 | 428 | 458 | 0.934 | 0.0000219 | 5839 |
Missense in Polyphen | 140 | 165.19 | 0.84753 | 2187 | ||
Synonymous | 1.37 | 146 | 169 | 0.866 | 0.00000878 | 1657 |
Loss of Function | 1.81 | 25 | 36.9 | 0.678 | 0.00000180 | 483 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00129 | 0.00129 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.00224 | 0.00222 |
European (Non-Finnish) | 0.000238 | 0.000237 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.00 | 0.00 |
Other | 0.00163 | 0.00163 |
dbNSFP
Source:
- Function
- FUNCTION: Serine/threonine kinase that plays a key role in M phase by acting as a regulator of mitosis entry and maintenance. Acts by promoting the inactivation of protein phosphatase 2A (PP2A) during M phase: does not directly inhibit PP2A but acts by mediating phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-62' and 'Ser-67', respectively. ARPP19 and ENSA are phosphatase inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase is essential to keep cyclin-B1-CDK1 activity high. Following DNA damage, it is also involved in checkpoint recovery by being inhibited. Phosphorylates histone protein in vitro; however such activity is unsure in vivo. May be involved in megakaryocyte differentiation. {ECO:0000269|PubMed:12890928, ECO:0000269|PubMed:19680222, ECO:0000269|PubMed:19793917, ECO:0000269|PubMed:20538976, ECO:0000269|PubMed:20818157}.;
- Disease
- DISEASE: Note=Defects in MASTL may play a role in the pathogenesis of thrombocytopenia, a disorder defined by reduced number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. {ECO:0000269|PubMed:12890928}.;
- Pathway
- MASTL Facilitates Mitotic Progression;Mitotic Prophase;M Phase;Cell Cycle;Cell Cycle, Mitotic
(Consensus)
Recessive Scores
- pRec
- 0.111
Intolerance Scores
- loftool
- 0.984
- rvis_EVS
- 1.14
- rvis_percentile_EVS
- 92.33
Haploinsufficiency Scores
- pHI
- 0.296
- hipred
- N
- hipred_score
- 0.170
- ghis
- 0.548
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0182
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mastl
- Phenotype
- embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype;
Zebrafish Information Network
- Gene name
- mastl
- Affected structure
- thrombocyte
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- G2/M transition of mitotic cell cycle;mitotic cell cycle;cellular response to DNA damage stimulus;female meiosis II;peptidyl-serine phosphorylation;negative regulation of phosphoprotein phosphatase activity;intracellular signal transduction;cell division;regulation of cell cycle;positive regulation of ubiquitin protein ligase activity
- Cellular component
- nucleus;nucleoplasm;cytoplasm;centrosome;cleavage furrow
- Molecular function
- protein serine/threonine kinase activity;ATP binding;kinase activity;protein phosphatase 2A binding